IL6 and non-small cell lung carcinoma: Although no survival data was available due to limited follow-up time, TCGA data revealed that NSCLC patients with a low IL6 level (n = 318, median survival time = 21.87 months) had longer overall survival than those with high IL6 (n = 314, median survival time = 26.33 months; P = 0.0006) (Fig. 6h).